You are viewing the site in preview mode

Skip to content


  • Poster presentation
  • Open Access

Development of the automated immunomonitoring system

  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 2
Journal for ImmunoTherapy of Cancer20142 (Suppl 3) :P153

  • Published:


  • Cell Culture
  • Patient Selection
  • Cell Response
  • Culture System
  • Clinical Development

Cancer vaccine which induces cytotoxic T lymphocyte targeting tumor associated antigens is one of major stream in cancer immunotherapy. Many cancer immunotherapy programs are in the clinical development all over the world and also the identification of biomarker for pharmacodynamics and patient selection should be considered.

Enzyme-linked immunospot (ELISPOT) assay is one useful method to detect antigen specific T cell response as an immunomonitoring. However, the standardization of the ELISPOT assay has not yet been established, and it has strongly been mandatory to detect accurate and objective immune response for clinical development of cancer vaccine. To overcome this problem, we have developed an automated immunomonitoring system, which performs cell culture processes including cell recovery, seeding and detection of the particular cells for ELISPOT assay. This automated cell culture system might be useful to control the quality of assays with cell culture and high-throughput outcomes. In this presentation, we show the concept and the characteristic of the automated immunomonitoring system.

Authors’ Affiliations

OncoTherapy Science, Inc., Kawasaki City, Japan
Panasonic Healthcare Co., Ltd., Minato-ku, Japan


© Osawa et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.